{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:32:57Z","timestamp":1792989177417,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.critrevonc.2025.104862","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:26:54Z","timestamp":1753313214000},"page":"104862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology"],"prefix":"10.1016","volume":"215","author":[{"given":"Matteo","family":"Ferro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-7660","authenticated-orcid":false,"given":"Felice","family":"Crocetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia Maria Ippolita","family":"Jannello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Contieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Veccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin Octavian","family":"Tataru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fallara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Chierigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Maria Cesare","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vartolomei Mihai","family":"Dorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Terracciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104862_bib1","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s12291-017-0688-8","article-title":"Diseases and Molecular Diagnostics: A Step Closer to Precision Medicine","volume":"32","author":"Dwivedi","year":"2017","journal-title":"Indian journal clinical biochemistry IJCB. India"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib2","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/iju.15338","article-title":"Urinary markers for bladder cancer diagnosis: A review of current status and future challenges","volume":"31","author":"Tomiyama","year":"2024","journal-title":"Int J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104862_bib3","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.7189\/jogh.13.04109","article-title":"The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040","volume":"13","author":"Zhang","year":"2023","journal-title":"J. Glob. Health"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib4","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.104862_bib5","unstructured":"Key Statistics for Bladder Cancer Available online [Internet]. Available from: https:\/\/www.cancer.org\/cancer\/types\/bladder-cancer\/about\/key-statistics.html (accessed on 2 April 2025)."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2023.03.029","article-title":"Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors","volume":"84","author":"Jubber","year":"2023","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.urolonc.2021.11.018","article-title":"Carcinogenic biomarkers of exposure in the urine of heated tobacco product users associated with bladder cancer: A systematic review","volume":"40","author":"Svendsen","year":"2022","journal-title":"Urol. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acs.chemrestox.4c00496","article-title":"A High-Affinity and Selective DNA Aptamer for the N-Linked C8-Deoxyguanosine Adduct Produced by the Arylamine Carcinogen 4-Aminobiphenyl","volume":"38","author":"Chen","year":"2025","journal-title":"Chem. Res Toxicol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104862_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12101745","article-title":"Advanced Bladder Cancer: Changing the Treatment Landscape","volume":"12","author":"Bilim","year":"2022","journal-title":"J. Pers. Med"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104862_bib10","first-page":"1980","volume":"324","author":"Lenis","year":"2020","journal-title":"Bladder Cancer A Review. JAMA."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib11","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/cam4.1979","article-title":"Hope and challenge: Precision medicine in bladder cancer","volume":"8","author":"Su","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib12","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11912-025-01645-7","article-title":"Advancements in the Diagnosis, Treatment, and Risk Stratification of Non-Muscle Invasive Bladder Cancer","volume":"27","author":"Smani","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104862_bib13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urolonc.2018.02.017","article-title":"The evolution of bladder cancer genomics: What have we learned and how can we use it?","volume":"36","author":"Audenet","year":"2018","journal-title":"Urol. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104862_bib14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41585-024-00872-0","article-title":"The evolving treatment landscape of metastatic urothelial cancer","volume":"21","author":"Roviello","year":"2024","journal-title":"Nat. Rev. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104862_bib15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clgc.2023.05.017","article-title":"Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis","volume":"21","author":"Ferro","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11523-024-01114-4","article-title":"Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis","volume":"20","author":"Yanagisawa","year":"2025","journal-title":"Target Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104862_bib17","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines","volume":"87","author":"van der Heijden","year":"2025","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104862_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11912-023-01390-9","article-title":"Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions","volume":"25","author":"Cockrell","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.32604\/or.2024.055155","article-title":"Biomarkers for predicting bladder cancer therapy response","volume":"33","author":"Mihai","year":"2025","journal-title":"Oncol. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker definitions and their applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med (Maywood)"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104862_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061630","article-title":"Biomarkers as Biomedical Bioindicators: Approaches and Techniques for the Detection, Analysis, and Validation of Novel Biomarkers of Diseases","volume":"15","author":"Ahmad","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.critrevonc.2025.104862_bib23","first-page":"12","article-title":"Detection of Urinary Molecular Marker Test in Urothelial Cell Carcinoma: A Review of Methods and Accuracy","author":"Bulai","year":"2022","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104862_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.euros.2024.09.001","article-title":"Xpert Bladder Cancer Detection in Emergency Setting Assessment (XESA Project): A Prospective","volume":"71","author":"Sordelli","year":"2025","journal-title":"SingleCent. Trial Eur. Urol. Open Sci."},{"key":"10.1016\/j.critrevonc.2025.104862_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.832835","article-title":"Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under \u201cActive Surveillance\u201d for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study","volume":"12","author":"Fasulo","year":"2022","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder","volume":"171","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104862_bib27","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104862_bib29","first-page":"10","article-title":"Clinical Validation of a Urine Test (Uromonitor-V2(\u00ae)) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients","author":"Sieverink","year":"2020","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104862_bib30","doi-asserted-by":"crossref","first-page":"1440626","DOI":"10.3389\/fonc.2024.1440626","article-title":"Application of artificial intelligence in the diagnosis and treatment of urinary tumors","volume":"14","author":"Zhu","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104862_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/ijp.ijp_442_23","article-title":"Genomic biomarkers: Unveiling the potential for precise cancer therapy response","volume":"55","author":"Kaur","year":"2023","journal-title":"Indian J. Pharmacol. India"},{"key":"10.1016\/j.critrevonc.2025.104862_bib32","first-page":"15","article-title":"ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma","author":"Zimpfer","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104862_bib33","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.8261","article-title":"Significance of TP53 mutation in bladder cancer disease progression and drug selection","volume":"7","author":"Wu","year":"2019","journal-title":"PeerJ"},{"key":"10.1016\/j.critrevonc.2025.104862_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: Treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104862_bib35","doi-asserted-by":"crossref","unstructured":"Kim W.J., Park S., Kim Y.J. Biomarkers in bladder cancer: present status and perspectives. Biomark Insights. 2007 Mar;2:95\u2013105.","DOI":"10.1177\/117727190700200018"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104862_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J. Mol. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib38","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","article-title":"FGFR Inhibition in Urothelial Carcinoma","volume":"87","author":"Li","year":"2025","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bpj.2014.11.3460","article-title":"Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization","volume":"108","author":"Del Piccolo","year":"2015","journal-title":"Biophys. J."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/12615","article-title":"Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas","volume":"23","author":"Cappellen","year":"1999","journal-title":"Nat. Genet"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104862_bib41","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1158\/1078-0432.CCR-05-1130","article-title":"Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors","volume":"11","author":"Zieger","year":"2005","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104862_bib42","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/S0002-9440(10)64665-2","article-title":"Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors","volume":"158","author":"Billerey","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib43","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum. Mol. Genet"},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104862_bib44","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104862_bib45","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1158\/0008-5472.CAN-09-0744","article-title":"Distinct microRNA alterations characterize high- and low-grade bladder cancer","volume":"69","author":"Catto","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104862_bib46","article-title":"Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers","volume":"24","author":"Ruiz de Porras","year":"2023","journal-title":"Int. J. Mol. Sci. Switz."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104862_bib47","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2217\/fon-2016-0042","article-title":"A place for precision medicine in bladder cancer: targeting the FGFRs","volume":"12","author":"di Martino","year":"2016","journal-title":"Future Oncol."},{"issue":"43","key":"10.1016\/j.critrevonc.2025.104862_bib48","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2024.39.e320","article-title":"FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development","volume":"39","author":"Kwon","year":"2024","journal-title":"J. Korean Med Sci."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib49","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion St","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104862_bib50","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104862_bib51","doi-asserted-by":"crossref","first-page":"490","DOI":"10.4254\/wjh.v16.i4.490","article-title":"Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept","volume":"16","author":"Wishahi","year":"2024","journal-title":"World J. Hepatol. U. S."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib52","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104862_bib53","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in Context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/biom10020307","article-title":"p53\u2019s Extended Reach: The Mutant p53 Secretome","volume":"10","author":"Pavlakis","year":"2020","journal-title":"Biomolecules"},{"issue":"7492","key":"10.1016\/j.critrevonc.2025.104862_bib55","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"characterization of urothelial bladder carcinoma","volume":"507","author":"Comprehensive molecular","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104862_bib56","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104862_bib57","doi-asserted-by":"crossref","first-page":"1057302","DOI":"10.3389\/fgene.2022.1057302","article-title":"TP53-related signature for predicting prognosis and tumor microenvironment characteristics in bladder cancer: A multi-omics study","volume":"13","author":"Tao","year":"2022","journal-title":"Front Genet"},{"issue":"22","key":"10.1016\/j.critrevonc.2025.104862_bib58","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1158\/0008-5472.CAN-06-2323","article-title":"p53 Attenuates cancer cell migration and invasion through repression of SDF-1\/CXCL12 expression in stromal fibroblasts","volume":"66","author":"Moskovits","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104862_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.590618","article-title":"A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer","volume":"11","author":"Wu","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib60","doi-asserted-by":"crossref","DOI":"10.1177\/1073274820976665","article-title":"Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition","volume":"27","author":"Lyu","year":"2020","journal-title":"Cancer Control"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib61","first-page":"784","article-title":"Two molecular pathways to transitional cell carcinoma of the bladder","volume":"54","author":"Spruck","year":"1994","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104862_bib62","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1128\/MCB.19.5.3395","article-title":"Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain","volume":"19","author":"Selivanova","year":"1999","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104862_bib63","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm0697-632","article-title":"Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53C-terminal domain","volume":"3","author":"Selivanova","year":"1997","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4161\/cbt.1.1.41","article-title":"The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein","volume":"1","author":"Takimoto","year":"2002","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib65","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1535-7163.MCT-14-0622-T","article-title":"Combined CDKN1A\/TP53 mutation in bladder cancer is a therapeutic target","volume":"14","author":"Liu","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104862_bib66","first-page":"15","article-title":"The Genomic Landscape of Urothelial Carcinoma with High and Low ERBB2 Expression","author":"Hadadi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104862_bib67","first-page":"1","article-title":"Systematic Review: Targeting HER2 in Bladder Cancer. Bladder","volume":"1","author":"Koshkin","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.06.021","article-title":"High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer","volume":"40","author":"Sikic","year":"2022","journal-title":"Urol. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104862_bib69","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/cas.14080","article-title":"Exosomes containing ErbB2\/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer","volume":"110","author":"Yoshida","year":"2019","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib70","first-page":"362","article-title":"Urothelial carcinomas: a focus on human epidermal receptors signaling","volume":"3","author":"Grivas","year":"2011","journal-title":"Am. J. Transl. Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib71","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","article-title":"Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours","volume":"60","author":"Fleischmann","year":"2011","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104862_bib72","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ijc.10731","article-title":"HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications","volume":"102","author":"Kr\u00fcger","year":"2002","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104862_bib73","doi-asserted-by":"crossref","first-page":"8463731","DOI":"10.1155\/2016\/8463731","article-title":"HER2 Protein Overexpression and Gene Amplification in Plasmacytoid Urothelial Carcinoma of the Urinary Bladder","volume":"2016","author":"Kim","year":"2016","journal-title":"Dis. Markers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s11523-024-01056-x","article-title":"Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer","volume":"19","author":"Leary","year":"2024","journal-title":"Target Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043720","article-title":"HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib76","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.clgc.2019.12.003","article-title":"HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter","volume":"18","author":"Yorozu","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib77","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur. Urol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104862_bib78","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4161\/cbt.29687","article-title":"Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib","volume":"15","author":"de Martino","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.critrevonc.2025.104862_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104862_bib80","article-title":"Advances in HER2-Targeted Treatment for Advanced\/Metastatic Urothelial Carcinoma","volume":"10","author":"Qu","year":"2023","journal-title":"Bladder (San. Fr. )"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104862_bib81","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib82","first-page":"699","article-title":"HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients","volume":"7","author":"Sasaki","year":"2014","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib83","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12672-024-01548-2","article-title":"Comprehensive analysis of single-cell and bulk RNA sequencing reveals postoperative progression markers for non-muscle invasive bladder cancer and predicts responses to immunotherapy","volume":"15","author":"Xiao","year":"2024","journal-title":"Discov. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib84","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104862_bib85","doi-asserted-by":"crossref","first-page":"1114203","DOI":"10.3389\/fonc.2023.1114203","article-title":"Identifying novel biomarkers associated with bladder cancer treatment outcomes","volume":"13","author":"Castaneda","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104862_bib86","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fonc.2018.00450","article-title":"Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data","volume":"8","author":"Giulietti","year":"2018","journal-title":"Front Oncol."},{"issue":"April","key":"10.1016\/j.critrevonc.2025.104862_bib87","article-title":"Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis","volume":"8","author":"Cicatiello","year":"2025","journal-title":"J. Liq. Biopsy [Internet]"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104862_bib88","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1158\/1078-0432.CCR-06-2940","article-title":"Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study","volume":"13","author":"Dyrskj\u00f8t","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104862_bib89","article-title":"An RNA-sequencing-based transcriptome for a significantly prognostic novel driver signature identification in bladder urothelial carcinoma","volume":"8","author":"Liu","year":"2020","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib90","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12967-021-02796-4","article-title":"Diagnostic performance of Oncuria\u2122, a urinalysis test for bladder cancer","volume":"19","author":"Hirasawa","year":"2021","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.critrevonc.2025.104862_bib91","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2147\/IJN.S72904","article-title":"Clinical and pathological implications of miRNA in bladder cancer","volume":"10","author":"Braicu","year":"2015","journal-title":"Int J. Nanomed."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib92","first-page":"37","article-title":"Bladder Cancer Molecular Taxonomy","volume":"2","author":"Lerner","year":"2016","journal-title":"Summ. a Consens. Meet. Bladder Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104862_bib93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11934-020-0960-y","article-title":"Genomic Subtyping in Bladder Cancer","volume":"21","author":"Jalanko","year":"2020","journal-title":"Curr. Urol. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104862_bib94","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.humpath.2015.09.015","article-title":"GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas","volume":"47","author":"Davis","year":"2016","journal-title":"Hum. Pathol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104862_bib95","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41585-023-00847-7","article-title":"Molecular profile of bladder cancer progression to clinically aggressive subtypes","volume":"21","author":"Guo","year":"2024","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104862_bib96","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur. Urol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104862_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2022.05.016","article-title":"Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer","volume":"40","author":"Ferro","year":"2022","journal-title":"Urol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104862_bib98","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1158\/1078-0432.CCR-04-2409","article-title":"Bladder cancer outcome and subtype classification by gene expression","volume":"11","author":"Blaveri","year":"2005","journal-title":"Clin. Cancer Res"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104862_bib99","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.21037\/tau-2019-mibc-12","article-title":"Update on bladder cancer molecular subtypes","volume":"9","author":"Fong","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.critrevonc.2025.104862_bib100","doi-asserted-by":"crossref","first-page":"FSO674","DOI":"10.2144\/fsoa-2020-0210","article-title":"Urologic malignancies: advances in the analysis and interpretation of clinical findings","volume":"7","author":"Crocetto","year":"2021","journal-title":"Future Sci. Oa. Engl."},{"key":"10.1016\/j.critrevonc.2025.104862_bib101","article-title":"FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104862_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17081283","article-title":"Novel Urinary Biomarkers for the Detection of Bladder Cancer","volume":"17","author":"Oyaert","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104862_bib103","first-page":"13","article-title":"Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement","author":"Ferro","year":"2023","journal-title":"Diagn. (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104862_bib104","doi-asserted-by":"crossref","first-page":"1487676","DOI":"10.3389\/fonc.2024.1487676","article-title":"Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities","volume":"14","author":"Ma","year":"2024","journal-title":"Front Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002501?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002501?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:37:51Z","timestamp":1792985871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":104,"alternative-id":["S1040842825002501"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104862","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging biomarkers in bladder cancer: Translating molecular advances into precision oncology","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104862"}}